Eupraxia Pharmaceuticals (EPRX) News Today $3.00 -0.19 (-5.96%) (As of 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Bayer Aktiengesellschaft (OTCMKTS:BAYRY) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) Head to Head ReviewDecember 17 at 3:21 AM | americanbankingnews.comEupraxia Pharmaceuticals Unveils Promising Drug Delivery DataNovember 21, 2024 | markets.businessinsider.comEupraxia presents new PK data from its Phase 2a Eosinophilic Esophagitis programNovember 20, 2024 | markets.businessinsider.comEupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNovember 20, 2024 | prnewswire.comEupraxia Pharmaceuticals reports regulatory updateNovember 16, 2024 | uk.investing.comEupraxia Pharmaceuticals Showcases Innovation at ACR 2024November 16, 2024 | markets.businessinsider.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Increased to Strong-Buy at RODMAN&RENSHAWRODMAN&RENSHAW upgraded Eupraxia Pharmaceuticals to a "strong-buy" rating in a report on Thursday.November 15, 2024 | marketbeat.comEupraxia Pharmaceuticals initiated with a Buy at Rodman & RenshawNovember 14, 2024 | markets.businessinsider.comEupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingNovember 14, 2024 | prnewswire.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated by Analysts at Rodman & RenshawRodman & Renshaw started coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $9.00 price target on the stock.November 14, 2024 | marketbeat.comEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024November 13, 2024 | prnewswire.comEupraxia reports data from RESOLVE Phase 1b/2a trialNovember 12, 2024 | markets.businessinsider.comEupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNovember 12, 2024 | prnewswire.comEupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | prnewswire.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 5.4% - What's Next?Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 5.4% - Should You Sell?November 7, 2024 | marketbeat.comEupraxia Pharmaceuticals Shares Rise After Completing Private PlacementNovember 1, 2024 | marketwatch.comEupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionOctober 31, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024October 28, 2024 | prnewswire.comEPRX:CA Eupraxia Pharmaceuticals Inc.October 18, 2024 | seekingalpha.comLancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisOctober 15, 2024 | prnewswire.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 3.4% - Here's What HappenedEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Up 3.4% - Should You Buy?October 12, 2024 | marketbeat.comEupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024October 10, 2024 | prnewswire.comEupraxia Pharmaceuticals Strengthens Senior Management TeamOctober 2, 2024 | prnewswire.comEPRX Eupraxia Pharmaceuticals Inc.September 22, 2024 | seekingalpha.comEupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal DiseasesSeptember 19, 2024 | prnewswire.comEupraxia reports positive EoE trial results, no severe adverse eventsSeptember 13, 2024 | uk.investing.comEupraxia reports positive data from eosinophilic esophagitis treatment trialSeptember 12, 2024 | msn.comEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisSeptember 11, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | prnewswire.comEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest UpdateEupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 123,500 shares, a growth of 175.7% from the July 31st total of 44,800 shares. Based on an average daily trading volume, of 13,700 shares, the days-to-cover ratio is presently 9.0 days. Approximately 0.4% of the company's stock are short sold.August 28, 2024 | marketbeat.comEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | prnewswire.comEupraxia Pharmaceuticals files report with SECAugust 4, 2024 | uk.investing.comEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt FacilityAugust 2, 2024 | prnewswire.comEupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Up 8.1%Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading 8.1% HigherJuly 26, 2024 | marketbeat.comClosing Bell: Eupraxia Pharmaceuticals Inc up on Wednesday (EPRX)July 25, 2024 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc up on Friday (EPRX)July 20, 2024 | theglobeandmail.comClosing Bell: Eupraxia Pharmaceuticals Inc down on Thursday (EPRX)July 20, 2024 | theglobeandmail.comEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and ExpoJuly 8, 2024 | prnewswire.comEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024July 3, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersJune 6, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024June 5, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisMay 23, 2024 | prnewswire.comEupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024May 22, 2024 | prnewswire.comEupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisMay 21, 2024 | prnewswire.comEupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024May 14, 2024 | prnewswire.com Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Amazon coin set to soar 25X – starting December 16th? (Ad)This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024 >3-Cent Amazon Coin< EPRX Media Mentions By Week EPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPRX News Sentiment▼0.000.57▲Average Medical News Sentiment EPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPRX Articles This Week▼11▲EPRX Articles Average Week Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cryoport News Today Design Therapeutics News Today Procaps Group News Today biote News Today Neurogene News Today Voyager Therapeutics News Today Contineum Therapeutics News Today Acelyrin News Today Kamada News Today Trevi Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPRX) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts